Skip to content
Review Open access

3D Bioprinting as an In Vitro Tool to Model the Tumor Microenvironment.

Nov 2026 · Seminars in Cancer Biology · pp. 102636 · 0 citations · 289 references
Medicine

Abstract

Three‑dimensional (3D) bioprinting has rapidly emerged as a powerful strategy for engineering physiologically relevant tumor microenvironment (TME) models that overcome the limitations of traditional 2D cultures and animal systems. The TME is a highly dynamic and heterogeneous ecosystem composed of malignant, stromal, immune, and vascular cells embedded within a biochemically and mechanically complex extracellular matrix (ECM). These components collectively regulate tumor progression, immune evasion, metastasis, and therapeutic resistance. Conventional preclinical models fail to capture this complexity, contributing to poor clinical translation of oncology therapeutics. Advances in extrusion‑based, inkjet, laser‑assisted, and stereolithographic bioprinting now enable spatially organized, multicellular constructs with tunable biochemical and biophysical cues that more accurately recapitulate TME architecture and function. Complementary innovations in biomaterials, microfluidics, and computational modeling further expand the capabilities of bioprinted systems for drug screening, mechanistic studies, and personalized medicine. This review summarizes the cellular and acellular components of the TME, outlines major bioprinting technologies and biomaterial strategies, and highlights emerging applications in cancer modeling. We also identify key research gaps and opportunities that must be addressed to advance bioprinted TME platforms toward robust, standardized, and clinically meaningful tools for precision oncology.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.